

ORIGINAL ARTICLE

Plasminogen activator-1 overexpression decreases experimental postthrombotic vein wall fibrosis by a non-vitronectin-dependent mechanism

A. T. OBI,* J. A. DIAZ,* N. L. BALLARD-LIPKA,* K. J. ROELOFS,* D. M. FARRIS,*
D. A. LAWRENCE,† T. W. WAKEFIELD* and P. K. HENKE*

*From the Conrad Jobst Vascular Research Laboratory, Section of Vascular Surgery, Department of Surgery, University of Michigan Medical School; and †Department of Medicine, University of Michigan Medical School, Ann Arbor, MI, USA

To cite this article: Obi AT, Diaz JA, Ballard-Lipka NL, Roelofs KJ, Farris DM, Lawrence DA, Wakefield TW, Henke PK. Plasminogen activator-1 overexpression decreases experimental postthrombotic vein wall fibrosis by a non-vitronectin-dependent mechanism. *J Thromb Haemost* 2014; 12: 1353–63.

Summary. *Background:* Factors associated with post-thrombotic syndrome are known clinically, but the underlying cellular processes at the vein wall are not well delineated. Prior work suggests that vein wall damage does not correlate with thrombus resolution but rather with plasminogen activator-1 (PAI-1) and matrix metalloproteinase (MMP) activity. *Objective:* We hypothesized that PAI-1 would confer post venous thrombosis (VT) vein wall protection via a vitronectin (Vn)-dependent mechanism. *Methods:* A stasis model of VT was used with harvest over 2 weeks, in wild-type, Vn^{-/-}, and PAI-1-overexpressing mice (PAI-1 Tg). *Results:* PAI-1 Tg mice had larger VT at 6 and 14 days, compared to controls, but Vn^{-/-} mice had no alteration of VT resolution. Gene deletion of Vn resulted in an increase in, rather than the expected decrease in, circulating PAI-1 activity. While both Vn^{-/-} and PAI-1 Tg had attenuated intimal fibrosis, PAI-1 Tg had significantly less vein wall collagen and a compensatory increase in collagen III gene expression. Both Vn^{-/-} and PAI-1 Tg vein wall had less monocyte chemoattractant factor-1 and fewer macrophages (F4/80), with significantly less MMP-2 activity and decreased TIMP-1 antigen. *Ex vivo* assessment of transforming growth factor β -mediated fibrotic response showed that PAI-1 Tg vein walls had increased profibrotic gene expression (collagens I and III, MMP-2, and α -smooth muscle actin) compared with controls, opposite of the *in vivo* response. *Conclusions:* The absence of Vn

increases circulating PAI-1, which positively modulates vein wall fibrosis in a dose-dependent manner. Translationally, PAI-1 elevation may decrease vein wall damage after deep vein thrombosis, perhaps by decreasing macrophage-mediated activities.

Keywords: fibrosis; PAI-1; postthrombotic syndrome; venous thrombosis; vitronectin.

Introduction

Deep venous thrombosis (DVT) is a significant health care problem in the United States, with 250 000 to 900 000 patients affected yearly [1,2]. An additional 200 000 patients are affected by the late sequelae of post thrombotic syndrome (PTS), characterized by leg pain, sensations of heaviness, limb edema, discoloration, and occasionally ulceration [3]. The end result after DVT is the conversion of a compliant, thin-walled vein with functional valves into a thick-walled vessel, often with non-functioning valves [4]. The physiological result of damaged veins is pooling of blood in the dependent extremities, producing venous hypertension and pain, fluid transudation, edema, and, in severe cases, ulceration.

Despite effective anticoagulant therapy treatments for DVT, there are no therapies that specifically target the PTS remodeling processes [5]. While surgical and interventional therapy may be beneficial for selected patients, treatment for PTS is mainly supportive, consisting of compression and wound care. Although compression therapy may provide symptomatic relief, it does not correct the fundamental changes that occur in the venous system. Indeed, recent data from a randomized controlled trial of compression for preventing PTS did not show a benefit compared with placebo [6]. An improved understanding of the biology of PTS, including potential therapeutic targets, is crucial in the effort to develop effective treatments.

Correspondence: Peter K. Henke, University of Michigan Health System, 1500 E. Medical Center Drive, Cardiovascular Center, 5463, Ann Arbor, MI 48109-5867, USA.
Tel.: +1 734 763 0250; fax: +1 734 647 9867.
E-mail: henke@umich.edu

Received 31 March 2014

Manuscript handled by: W. Aird

Final decision: P. H. Reitsma, 12 June 2014

We have recently shown the importance in plasminogen activator-1 (PAI-1) in post-DVT vein wall remodeling [7]. Gene deletion of PAI-1 hastened venous thrombus resolution in a mouse model of stasis DVT but resulted in a thickened and collagen-rich vessel wall. Thrombin-anti-thrombin levels were not elevated in the thrombi of PAI-1-null mice, suggesting that the mechanism of increased fibrosis was not due to PAI-1's thrombin inhibitory activity but possibly to its role in binding vitronectin (Vn), an abundant plasma glycoprotein.

Vitronectin is produced by the liver and found circulating at appreciable levels in the plasma, in the α -granules of platelets, and in the extracellular matrix [8]. It plays a multifaceted role in vascular biology, particularly with regard to thrombogenesis, pericellular proteolysis, leukocyte recruitment, and cellular adhesion/migration [8,9]. Vn has been associated with fibrosis of organ systems such as liver [10,11] and lung [12,13] and implicated as a mediator of neointima formation in the arterial vasculature [14–16]. To date, its effect on post thrombotic venous remodeling is unknown.

Experimental models of arterial thrombosis differ with regard to the role of Vn, with some data suggesting that it plays a key role in promoting arterial thrombogenesis [17] and stabilization of thrombi [18], while other data suggest an inhibitory role in thrombogenesis [19]. However, little is understood about how or if Vn contributes to venous thrombosis (VT), with only one study to date demonstrating increased time to occlusion in Vn^{-/-} mice undergoing photochemically induced thrombosis of the jugular vein [17]. In this study, we hypothesize that (i) Vn inhibits thrombus resolution via stabilization of PAI-1 and (ii) Vn contributes to vein wall fibrosis via increased monocyte vein wall infiltration.

Methods

Animals

Male C57BL/6 (wild-type [WT]) mice (Jackson Laboratory, Farmington, CT), Vn gene-deleted (Vn^{-/-}) mice [20] (backcrossed > 10 generations on C57BL/6 mice), and PAI-1-overexpressing mice (PAI-1 Tg, backcrossed > 10 generations on C57BL/6 background) [21] were used in this study. Initial pilot studies comparing homozygous littermates without transgene (PAI-1 Tg littermates) to C57BL/6 controls demonstrated identical phenotype with regard to VT (similar size and cellular morphology). Thus, in the interest of humane and responsible animal use, C57BL/6 mice were used as controls (rather than homozygous littermates) for all experiments. Animals ranged from 8 to 10 weeks of age with average weight of 24.2 g (WT), 24.4 g (Vn), and 24.6 g (PAI-1 Tg). All work was approved by the University of Michigan Committee on Use and Care of Animals and was performed in compliance with the "Guide for the Care and Use of Laboratory Animals" published by the U.S. National Institutes of Health.

Model of DVT

A DVT model of IVC ligation, or stasis thrombosis, was performed as described previously [22]. Briefly, mice were anesthetized via 2% inhaled isoflurane. Inferior vena cava (IVC) exposure was gained via midline laparotomy, and dorsal branches were interrupted with electrocautery. Side branches and the infrarenal IVC were ligated with 7-0 Prolene (Ethicon, Inc, Somerville, NJ, USA) to generate blood stasis and ultimately thrombosis. Fascial closure was performed with 5-0 Vicryl suture and skin closure with Vetbond tissue adhesive (3M Animal Care Products, St. Paul, MN, USA). Mice were euthanized at 2, 6, and 14 days postthrombosis with the collection of plasma, vein wall, and thrombus. The vein wall and the thrombus were harvested separately at all time points [22,23]. Before processing, the IVC and its associated thrombus were weighed (grams) and measured (centimeters). Thrombus weight, encompassing the thrombus and the vein wall, was used as a measure of thrombosis resolution [22,24].

Gelatin zymography of matrix metalloproteinase-2 and -9

Gelatin substrate zymography was performed using pre-cast 10% sodium dodecylsulfate (SDS)-polyacrylamide gels containing 1 mg mL⁻¹ gelatin (unless otherwise stated, all zymographic supplies were from Novex, San Diego, CA, USA) [25–27]. Vein wall tissue was homogenized in SDS, centrifuged for 10 min at 2000 × g. Supernatants were aliquoted equally and diluted with Tris-glycine-SDS sample buffer and electrophoretically separated under non-reducing conditions. Separated proteins were re-natured in 2.7% Triton X-100 for 2 h to induce gelatin lysis by re-natured matrix metalloproteinases (MMPs). The gels were developed for 48 h at 37 °C in 50 mmol L⁻¹ Tris-HCl, 5 mmol L⁻¹ CaCl₂, and 0.2% Brij 35, followed by staining with Coomassie Blue and destaining in 10% acetic acid. MMP activity was evident by clear bands against a darkly stained background where the substrate has been degraded by the enzyme. Samples containing human recombinant MMP-2 and MMP-9 (Oncogene, Boston, MA, USA) were included as standards. Concentrations of the densitometry analysis were performed using a FOTO/Analyst CCD CAMERA (Fotodyne, Hartland, WI, USA) and GEL-Pro Analyzer software version 3.1 (Media Cybernetics, Silver Springs, MD, USA). Ratios of optical densities/total protein were calculated. Results were normalized to total protein using a bicinchoninic acid protein assay kit, assessing colorimetric detection and quantification of total protein, which was read between 560 and 590 nm (Pierce, Rockford, IL, USA).

Antigen determination

Antigen determination via enzyme linked immunosorbent assay (ELISA) was performed on vein wall

homogenate for monocyte chemotactic protein 1 (MCP-1), interleukin (IL)-1 β , and IL-13 (R&D Systems, Minneapolis, MN, USA). Samples were aliquoted in duplicate on plates precoated with appropriate capture antibody and then detected by use of a biotinylated antibody, followed by tetramethylbenzidine substrate according to the manufacturer's protocol. The results were read on an Elx808 plate reader (Biotek, Winooski, VT, USA) at a 450-nm wavelength. Total protein was measured by using a bicinchoninic acid protein assay kit, as detailed in the preceding section. Results were normalized to total protein (mg).

PAI-1 activity assay

To measure active murine PAI-1 concentrations in plasma samples, human urokinase plasminogen activator (Abcam, Cambridge, MA, USA) was coupled to carboxylated beads (Luminex) and used to capture active PAI-1. A standard curve was generated using known concentrations of murine PAI-1 in PAI-1-depleted mouse plasma (Molecular Innovations, Novi, MI, USA). The sample, 10 μ L PBS-1% BSA, and 5000 beads in 30 mL of PBS-1% BSA were incubated overnight at 4 °C. The beads were mixed with biotin-labeled rabbit anti-mouse PAI-1 (Molecular Innovations) followed by the addition of streptavidin-R-phycoerythrin (Molecular Probes). The beads were then read with the Luminex 100 (median setting, 100 mL sample size, 100 events/bead).

Real-time quantitative polymerase chain reaction (RT-PCR)

Immediately on harvest, vein wall segments were preserved in TRIzol reagent. The samples underwent reverse transcription with the addition of oligo(dT) primer and dNTP at 65 °C for 5 min followed by first strand buffer, dithiothreitol, and ribonucleoside inhibitor at 37 °C for 2 min. M-MLV Reverse Transcriptase (Life Technologies, Carlsbad, CA, USA) was added and RNA heated to 37 °C for 50 min and then 70 °C for 20 min. The resultant cDNA was amplified by Taq polymerase in the Rotogene qPCR system (Qiagen Inc, Valencia, CA, USA). Rotogene quantification uses the cycle threshold (Ct) for the gene of interest normalized to the housekeeping gene β -actin. Relative mRNA expression is calculated by the formula $2^{-\text{(Ct target gene - Ct reference gene)}}$, and cycle lengths used are within the exponential phase of the PCR [28]. These primers included β -actin, procollagen (Col)1a2, Col3a, MMP-2, and α -smooth muscle actin (α -SMA).

Histology, immunohistochemistry, and collagen staining

The IVC and associated thrombi were harvested *en bloc*, fixed in formalin, embedded in paraffin, and cut into 5- μ m sections as previously described [29,30]. Vein wall

monocyte cell counts were performed following staining with F4/80 antibody (1:100; Abcam, Cambridge, MA, USA). Briefly, non-specific binding sites were blocked with normal serum, and primary antibody was added, followed by biotin-labeled secondary antibody (rat IgG). An avidin-biotin-peroxidase complex was performed according to manufacturer's instructions (Vector Laboratories Inc, Burlingame, CA, USA), and the slides were counterstained with hematoxylin and eosin. Monocyte cell counts of five representative high-power fields of both vein wall and thrombus were performed in a blinded fashion [31].

Collagen content was quantified with Picosirius red stain as previously described [7,32,33]. These sections were then analyzed in crossed-plane polarized light from a monochromatic source to assess cross-linked collagen. Two images for each were obtained using a Zeiss Axio M1 scope and Zeiss AxioVision software (Carl Zeiss Microimaging GmbH, Göttingen, Germany) at 0 and 90 degrees to the plane of polarization, to capture the birefringence of fibers extinguished in one direction. The images were analyzed blindly using NIH ImageJ software. The IVC wall was outlined as a region of interest, and then the image underwent threshold segmentation to differentiate collagen from other (primarily cellular and empty space) components of the vein wall. A vein wall collagen score was assigned by using the formula $[(\% \text{ birefringent area}) \times (\text{measured vein wall area})]/(\text{total specimen area})$.

To account for non-collagen vein wall changes, intimal thickness and fibrosis scoring assessed from hematoxylin and eosin-stained sections were scored by a board-certified veterinary pathologist in a blinded manner as previously described [7,22,31]. Briefly, the scoring system ranges from a score of 0 (no evidence of fibrosis) to 3 (intima contains numbers fibroblasts and is irregularly thickened by large amounts of collagenous connective tissue). A consistent mid-section thrombosed IVC segment was used for all histological analysis [34–36].

Ex vivo methods of vein wall assessment

The IVC was harvested in control mice (WT and PAI-1 Tg), placed in cold Dulbecco phosphate-buffered saline with 2 \times penicillin/streptomycin/glutamine (Gibco, Invitrogen, Carlsbad, CA, USA), and cleaned by using a dissecting microscope [24,34,37]. The vein wall was divided lengthwise and weighed, and each half was further divided into three or four pieces. The vein was incubated in Dulbecco modified Eagle medium (Gibco) containing 5% FCS and 1% penicillin streptomycin gentamycin with or without transforming growth factor (TGF)- β 1 (10 μ g mL⁻¹, mouse recombinant; R&D Systems) in a 12-well plate [38]. The tissue culture was incubated for 24 h at 37 °C in 5% carbon dioxide. The wet

weight of the vein wall was recorded, and the samples were gently washed in Dulbecco modified Eagle medium, placed in TRIzol, and frozen at -80°C for RT-PCR processing.

Statistical analyses

All statistical analyses were performed using GraphPad Prism version 6.01 for Windows (GraphPad Software, San Diego, CA, USA). The statistical differences between groups were determined by using an unpaired *t*-test with Welch's correction, one-way ANOVA analysis with Tukey's multiple comparison test, or Dunnett's multiple comparison test as deemed appropriate. Data are reported as mean \pm standard error of the mean (SEM), and differences are considered significant at a *P* value of ≤ 0.05 . Animal numbers (*n*) for experiments were predetermined based on independent statistical review, protocols, and numbers needed for significance. For an $\alpha = 0.5$ and power of 80%, *n* = 5 is sufficient for immunological tests and *n* = 10 is sufficient for zymography.

Results

Vn^{-/-} mice have paradoxically increased circulating PAI-1 activity

Despite the recent commercial availability of *Vn*^{-/-} mice and subsequent increase in use, no studies have characterized levels of circulating active PAI-1 in these animals. PAI-1 activity as measured in control mice and at three time points postthrombosis (2, 6, and 14 days) is demonstrated in Fig. 1. Both total and active PAI-1 levels were elevated in the *Vn*^{-/-} mice compared to WT mice. Contrary to expectations, we found active PAI-1 elevated 36-fold compared to WT mice (Fig. 1A) and total circulating PAI-1 to be elevated 10-fold in *Vn*^{-/-} mice (Fig. 1B). Active PAI-1 remained elevated in the *Vn*^{-/-} mice following thrombosis with significant elevations at days 6 and 14, with 82-fold and 39-fold increase over WT, respectively (Fig. 1C), with similar elevations seen of total PAI-1 (Fig. 1D). To determine whether the results we found with regard to thrombus resolution and vein




Fig. 1. Both active and total PAI-1 were elevated in transgenic PAI-1-overexpressing mice (PAI-1 Tg) compared to WT (*n* = 5 for all groups) at baseline (A, B) and following induction of deep venous thrombosis (C, D), with intermediate levels of PAI-1 in the *Vn*^{-/-} depleted mice (****P* < 0.001, *****P* < 0.0001).

wall fibrosis were truly due to alterations in PAI-1 activity in these animals or rather a secondary function of Vn, we included a comparison cohort of PAI-1 Tg with normal endogenous Vn. Levels of active circulating PAI-1 in these animals were markedly elevated at baseline (137-fold) and postthrombosis (15- to 412-fold) compared to WT (Fig. 1A, C). Similar elevations were seen in total PAI-1 at baseline (172-fold) and postthrombosis compared to WT (10- to 54-fold) (Fig. 1B, D).

Venous thrombogenesis and thrombus resolution are unaffected by $Vn^{-/-}$

Thrombus weights during acute thrombogenesis, as measured at day 2, were similar between WT and $Vn^{-/-}$ mice (Fig. 2A). Thrombus resolution, as measured by thrombus weight at 6 and 14 days postthrombosis (Fig. 2B), was also unaffected by $Vn^{-/-}$. Transgenic PAI-1-overexpressing mice exhibited impairment of thrombus resolution, with increased residual thrombus weight at 6 and 14 days postthrombosis (Fig. 2B). However, thrombogenesis (2 days) was not affected in these animals (Fig. 2A).

Vein wall fibrosis is attenuated by excess PAI-1

Vein wall fibrosis, intimal thickness, and collagen content were assessed at day 14, and collagen gene expression assessed at days 6 and 14. Vein wall fibrosis was significantly diminished in mice with elevated PAI-1 ($Vn^{-/-}$ mice and




Fig. 2. Neither $Vn^{-/-}$ gene deletion nor PAI-1 overexpression affected thrombogenesis, as measured by thrombus weight 2 days postthrombosis, in the deep venous system (A, all $n > 25$). Thrombus resolution was impaired in the PAI-1 Tg mice but not in the $Vn^{-/-}$ mice (B, all $n > 25$, * $P < 0.05$, **** $P < 0.0001$).

PAI-1 Tg) at day 14 compared to WT (Fig. 3B). Total vein wall collagen content, as measured by Picrosirius red staining [7], demonstrated a stepwise reduction with increasing levels of circulating PAI-1 (Fig. 3A, E, F). Decreases in vein wall fibrosis at day 14 were accompanied by a paradoxical increase in procollagen I and III α gene expression in $Vn^{-/-}$ (3.7- and 2.1-fold) and PAI-1 Tg (5.3- and 4.7-fold) mice compared to controls (Fig. 3C, D).

PAI-1 inhibits monocyte recruitment and influx

MCP-1 peaks during the early and middle stages of thrombus resolution, drives monocytes chemotaxis, and is implicated in clearance of residual thrombus [39–41]. At these time points (days 2 and 6), MCP-1 levels were suppressed by $\geq 50\%$ in mice with elevated PAI-1 ($Vn^{-/-}$ and PAI-Tg), both in the vein wall (Fig. 4A) and in the thrombus (Fig. 4B). This correlated with diminished vein wall (Fig. 4C, E–G) and thrombus (Fig. 4D–G) monocyte influx at day 14 as measured by positively staining F4/80 cells and impaired thrombus resolution (Fig. 2B) in mice with markedly elevated circulating PAI-1 (PAI-1 Tg).

Vein wall MMP activity is inversely related to PAI-1 activity

The target of PAI-1 inhibition, plasmin, can serve as an activator of MMP-2 and -9 [42–44]. Furthermore, monocytes represent a source of MMPs in the postthrombotic vein wall [29], and recruitment is altered in the presence of excess PAI-1 (Fig. 4C). In mice with PAI-1 ($Vn^{-/-}$ and PAI-1 Tg) elevation, total MMP-9 and -2 levels were diminished in the postthrombotic vein wall (Fig. 5A, B). Vein wall TIMP-1 antigen did not account for inhibition of MMPs and was actually decreased at 6 and 14 days in $Vn^{-/-}$ and PAI-1 Tg mice compared to WT (Fig. 5C).

Genetic alterations in Vn and PAI-1 result in altered inflammatory cytokine milieu

Proinflammatory cytokine IL-1 β is upregulated in the postthrombotic vein wall [41] and augments PAI-1 production by endothelial cells [45–47]. We found that in animals with very high levels of PAI-1, peak vein wall IL-1 β upregulation was attenuated (Fig. 6A). Consistent with the antifibrotic phenotype of the PAI-1 Tg mice, we found a reduction of IL-13 in the vein wall at early and mid time points postthrombosis (Fig. 6B). The $Vn^{-/-}$ mice exhibited an intermediate vein wall cytokine profile: IL-1 β levels approximated those of the PAI-1 Tg mice and IL-13 levels approximated those of the WT.

PAI-1 Tg vein walls are not antifibrotic *ex vivo*

Given that vein wall fibrosis was reduced in PAI-1 overexpressing mice, we asked if the altered genotype affected the fibrotic response *ex vivo*. We used our organ culture




Fig. 3. At 2 weeks postthrombosis collagen content was inversely related to PAI-1 activity with PAI-1 Tg mice exhibiting nearly a 50% reduction compared to WT at day 14 (A, E–G, $n = 5$, $*P < 0.05$). Cellular fibrotic changes (B, $n = 5$) were inversely associated with levels of PAI-1. Compared to WT, collagen I and III α gene expression was increased in mice with lowest vein wall collagen deposition (C, D, $n = 5$ –10, $**P < 0.01$, $***P < 0.001$). Decreased collagen content is evident in vein wall stained with Sirius Red in Vn (F) and PAI-1 Tg (G) compared to WT (E; T = thrombus).

model [37] to assess the response to fibrotic mediator TGF- β (Fig. 7). Consistent with the increases seen *in vivo* with increased procollagen I and III α gene expression in response to thrombosis compared to WT (Fig. 3C, D), the *ex vivo* cultured vein wall demonstrated an increase in procollagen gene expression in response to fibrotic stimulation with TGF- β (Fig. 7A, B). Additional proteins associated with fibrotic injury, MMP-2 (Fig. 7C) and α -SMA [37] (Fig. 7D), demonstrated increased relative gene

expression in PAI-1 Tg mice vein wall, suggesting that the antifibrotic effect of PAI-1 overexpression was not due to fundamental changes in vein wall gene expression but rather the antifibrotic effect of circulating PAI-1.

Discussion

Vein wall fibrosis after DVT, clinically manifested as PTS, is a problem with no known direct therapy. Thus, defining the




Fig. 4. MCP-1 was significantly decreased in Vn^{-/-} and PAI-1 Tg mice in both the vein wall (A) and thrombus at days 2 and 6 (B, $n = 5-10$). Vein wall monocyte influx (C) but not intrathrombus monocyte influx (D) at day 14 was significantly suppressed in Vn^{-/-} and PAI-1 Tg mice ($n = 4-5$). E-G, representative photomicrographs at $\times 100$ of WT (E), Vn^{-/-} (F) and PAI-1 Tg (G) mice stained with monocyte specific antibody F4/80. T = thrombus. * $P \leq 0.05$, ** $P \leq 0.01$, *** $P \leq 0.001$, **** $P \leq 0.0001$ by analysis of variance with Dunnett's multiple comparison test.

mechanisms of vein wall fibrosis is important translationally. In this study, we have shown the following: (i) contrary to findings in arterial injury models [17-19], the presence of Vn does not influence the amplitude of thrombogenesis or thrombus resolution; (ii) Vn^{-/-} mice have increased circulating active and total PAI-1 levels; (iii) elevation of PAI-1 is protective against vein wall fibrosis and inversely correlates with vein wall MMP activity; (iv) elevation of PAI-1 is associated with decreased monocyte infiltrate and altered cytokine profile; and (v) these effects do not appear to be due to genotype-specific alterations in the vein wall but rather to the antifibrotic effect of circulating PAI-1.

A significant role of PAI-1 in vascular thrombosis and thrombus resolution has been confirmed in both animal

and human studies [48]. Consistent with previous data suggesting that PAI-1 gene deletion does not affect venous thrombogenesis, we found here that PAI-1 overexpression failed to affect initial thrombus weight [49]. However, the role of PAI-1's 'cofactor' Vn remains understudied, with few animal studies evaluating thrombotic potential in Vn^{-/-} mice and none specifically evaluating the deep venous system [17-19]. In a small vessel model of photochemically induced VT, thrombogenesis was impaired in Vn^{-/-} mice [17]. This contrasts to our data, which demonstrate that in the deep vein system, at the time of peak thrombogenesis, there was no difference between thrombus weight and size in Vn^{-/-} and WT mice. The discrepancy between these results suggest that




Fig. 5. Vein wall MMP-9 (A) and -2 (B, all $n = 8-12$, *** $P < 0.001$, **** $P < 0.0001$) activity is diminished during thrombus resolution (6d and 14d) in $Vn^{-/-}$ and PAI-1 Tg mice compared to WT controls. TIMP-1 levels were similarly decreased in PAI-1 Tg mice and $Vn^{-/-}$ vein wall (C, $n = 5-10$ * $P < 0.05$, ** $P < 0.01$).




Fig. 6. IL-1 β was reduced in the vein wall at early and mid-time points postthrombosis (A, all $n = 5-10$, * $P < 0.05$) in $Vn^{-/-}$ and PAI-1 Tg mice. PAI-1 Tg but not $Vn^{-/-}$ mice demonstrated a reduction in IL-13 at 2 days postthrombosis (B).

Vn may function very early in thrombogenesis, as the photochemical model was used to study early thrombus formation at a very early time point (3–24 h), or that Vn

is less essential to stasis-induced thrombus formation. Furthermore, Vn deletion does not hasten thrombus resolution, in contrast with PAI-1^{-/-} mice [7]. These findings are supported by elevation of active PAI-1 levels in $Vn^{-/-}$ mice, perhaps due to inability of PAI-1 to remain localized to site of fibrin formation or extracellular matrix via its interaction with Vn . Transgenic overexpression of PAI-1, which produced levels 3 to 17 times higher than those of the $Vn^{-/-}$ mice, resulted in incremental inhibition of thrombus resolution with larger VT, suggesting that the effect of PAI-1 on thrombus resolution is likely dose dependent.

Although genetic deletion of PAI-1 is associated with increased fibrinolysis by secondary increasing plasmin activity and smaller VT, an increase in vein wall fibrosis was observed [7]. PAI-1's role in organ fibrosis is complex and dependent on the animal model. For example, divergent results with PAI-1 deletion exist in arterial injury models, with increased medial hyperplasia after wire injury [50], or decreased medial hyperplasia after ferric chloride injury [51]. From the current study, the mechanisms of PAI-1 antifibrotic effect are likely two-fold; first, significantly decreased MMP-2 and -9 activity in the postthrombotic vein wall was found. Elevation of both MMPs is associated with postthrombotic vein wall fibrosis [37,52,53], and a reduction is consistent with attenuated fibrotic injury. Second, fewer macrophages (and consistently decreased MCP-1) were found in the vein wall and thrombus of PAI-1 Tg and $Vn^{-/-}$ mice. While macrophages may have profibrotic or antifibrotic activities [54], it is likely in the current experiments that less profibrotic signaling was present in the PAI-1 Tg mice. In lung injury models, IL-1 β [55] and IL-13 [56] are profibrotic. Consistently, in the current model, IL-1 β and IL-13 were significantly elevated in WT mice postthrombosis, and reduction of these profibrotic mediators may also account for the observed reduction in fibrotic injury.




Fig. 7. *Ex vivo* vein wall response to profibrotic stimuli with TGF- β demonstrates divergent response between WT and PAI-1 Tg mice. As compared with saline-treated controls, TGF- β administration was associated with a significant increase in procollagen I, III α , MMP-2 and α -SMA gene expression in PAI-1Tg vein wall compared to WT (A–D, all $n = 5$, * $P < 0.05$, ** $P < 0.01$).

Binding of PAI-1 to its ‘cofactor’ Vn stabilizes and confers PAI-1 to a longer half-life, contributing to local antifibrinolytic activity but also indirectly enhancing the antiadhesive functions of PAI-1. PAI-1 competes with monocyte surface receptor urokinase plasminogen activator receptor for the NH₂ terminus of Vn [8]. Binding of PAI-1 displaces urokinase plasminogen activator receptor and inhibits monocyte adhesion [57]. Vn also exhibits a variety of PAI-1-independent activities, including increasing cellular migration [13] and vascular permeability [58]. Interestingly, the vein walls from PAI-1 Tg mice were not intrinsically resistant to a profibrotic stimulus. Indeed, using a low TGF- β dose, we found PAI-1 Tg vein walls were more likely to have increased collagen gene expression and fibrotic gene markers of MMP-2 and α -SMA. This suggests that the antifibrotic phenotype associated with elevated PAI-1 in our model was not the result of genotype-specific decreased vein wall susceptibility to fibrosis but more likely the antifibrotic effect of circulating PAI-1.

Postthrombotic vein wall injury is complex, and new data suggest that compression therapy may not be truly effective [59]. New and specific therapies are needed, particularly since aggressive thrombolysis may be limited to specific good-risk patients within an early timeframe, and carries a risk of life-threatening hemorrhage [60]. In this study, we demonstrated that increased circulating PAI-1, either from gene deletion of PAI-1 ligand Vn or in setting of transgenic overexpression, is associated with attenuated fibrosis of the postthrombotic vein wall. While it is unlikely that exogenous PAI-1 would be practical as it would impair thrombus resolution, interruption of PAI-1–fibrin interaction via specific targeting of vitronectin [61] has the potential to decrease vein wall fibrotic response without affecting thrombus resolution and represents a future area of study.

Addendum

P. K. Henke, T. W. Wakefield, and D. A. Lawrence were responsible for study conception and design. N. L. Ballard-Lipka, K. J. Roelofs, D. M. Farris, and A. T. Obi were responsible for data collection and experimentation. A. T. Obi, P. K. Henke, T. W. Wakefield, D. A. Lawrence, and J. A. Diaz were responsible for analysis and interpretation. A. T. Obi and P. K. Henke were responsible for writing the article. P. K. Henke, T. W. Wakefield, D. A. Lawrence, and J. A. Diaz were responsible for critical revision of the article. P. K. Henke, T. W. Wakefield, and D. A. Lawrence were responsible for obtained funding. P. K. Henke had overall responsibility.

Disclosure of Conflict of Interest

The authors state that they have no conflicts of interests.

Acknowledgements

Presented in part at the 25th Meeting of the American Venous Forum, Phoenix, AZ, February 2013. Supported by grants HL092129 (PKH), National Institutes of Health 5 T32 HL076123-09 (TW and AO), and HL089407 (DL and TW).

References

- Deitelzweig SB, Johnson BH, Lin J, Schulman KL. Prevalence of clinical venous thromboembolism in the USA: current trends and future projections. *Am J Hematol* 2011; **86**: 217–20.
- Lloyd-Jones D, Adams RJ, Brown TM, Carnethon M, Dai S, De Simone G, Ferguson TB, Ford E, Furie K, Gillespie C, Go A, Greenlund K, Haase N, Hailpern S, Ho PM, Howard V, Kissela B, Kittner S, Lackland D, Lisabeth L, et al. Heart Disease and Stroke Statistics–2010 Update. A Report From the American Heart Association. *Circulation* 2009; **119**: e21–181.
- Bergan JJ, Schmid-Schonbein GW, Smith PD, Nicolaides AN, Boisseau MR, Eklof B. Chronic venous disease. *N Engl J Med* 2006; **355**: 488–98.
- Johnson BF, Manzo RA, Bergelin RO, Strandness DE Jr. Relationship between changes in the deep venous system and the development of the postthrombotic syndrome after an acute episode of lower limb deep vein thrombosis: a one- to six-year follow-up. *J Vasc Surg* 1995; **21**: 307–12.
- Henke PK, Comerota AJ. An update on etiology, prevention, and therapy of postthrombotic syndrome. *J Vasc Surg* 2011; **53**: 500–9.
- Kahn SR, Shapiro S, Wells PS, Rodger MA, Kovacs MJ, Anderson DR, Tagalakis V, Houweling AH, Ducruet T, Holcroft C, Johri M, Solymoss S, Miron MJ, Yeo E, Smith R, Schulman S, Kassis J, Kearon C, Chagnon I, Wong T, et al. Compression stockings to prevent post-thrombotic syndrome: a randomised placebo-controlled trial. *Lancet* 2014; **383**: 880–8.
- Baldwin JF, Sood V, Elfline MA, Luke CE, Dewyer NA, Diaz JA, Myers DD, Wakefield T, Henke PK. The role of urokinase plasminogen activator and plasmin activator inhibitor-1 on vein wall remodeling in experimental deep vein thrombosis. *J Vasc Surg* 2012; **56**: 1089–97.
- Preissner KT, Reuning U. Vitronectin in vascular context: facets of a multitaled matricellular protein. *Semin Thromb Hemost* 2011; **37**: 408–24.
- Stefansson S, Haudenschild CC, Lawrence DA. Beyond fibrinolysis: the role of plasminogen activator inhibitor-1 and vitronectin in vascular wound healing. *Trends Cardiovasc Med* 1998; **8**: 175–80.
- Patsenker E, Popov Y, Wiesner M, Goodman SL, Schuppan D. Pharmacological inhibition of the vitronectin receptor abrogates PDGF-BB-induced hepatic stellate cell migration and activation in vitro. *J Hepatol* 2007; **46**: 878–87.
- Koukoulis GK, Shen J, Virtanen I, Gould VE. Vitronectin in the cirrhotic liver: an immunomarker of mature fibrosis. *Hum Pathol* 2001; **32**: 1356–62.
- Courey AJ, Horowitz JC, Kim KK, Koh TJ, Novak ML, Subbotina N, Warnock M, Xue B, Cunningham AK, Lin Y, Goldklang MP, Simon RH, Lawrence DA, Sisson TH. The vitronectin-binding function of PAI-1 exacerbates lung fibrosis in mice. *Blood* 2011; **118**: 2313–21.
- Lazar MH, Christensen PJ, Du M, Yu B, Subbotina NM, Hanson KE, Hansen JM, White ES, Simon RH, Sisson TH. Plasminogen activator inhibitor-1 impairs alveolar epithelial repair by binding to vitronectin. *Am J Respir Cell Mol Biol* 2004; **31**: 672–8.
- Peng L, Bhatia N, Parker AC, Zhu Y, Fay WP. Endogenous vitronectin and plasminogen activator inhibitor-1 promote neointima formation in murine carotid arteries. *Arterioscler Thromb Vasc Biol* 2002; **22**: 934–9.
- Coleman KR, Braden GA, Willingham MC, Sane DC. Vitaxin, a humanized monoclonal antibody to the vitronectin receptor (alpha v beta 3), reduces neointimal hyperplasia and total vessel area after balloon injury in hypercholesterolemic rabbits. *Circ Res* 1999; **84**: 1268–76.
- Dufourcq P, Couffignal T, Alzieu P, Daret D, Moreau C, Duplaa C, Bonnet J. Vitronectin is up-regulated after vascular injury and vitronectin blockade prevents neointima formation. *Cardiovasc Res* 2002; **53**: 952–62.
- Eitzman DT, Westrick RJ, Nabel EG, Ginsburg D. Plasminogen activator inhibitor-1 and vitronectin promote vascular thrombosis in mice. *Blood* 2000; **95**: 577–80.
- Konstantinides S, Schafer K, Thinnis T, Loskutoff DJ. Plasminogen activator inhibitor-1 and its cofactor vitronectin stabilize arterial thrombi after vascular injury in mice. *Circulation* 2001; **103**: 576–83.
- Fay WP, Parker AC, Ansari MN, Zheng X, Ginsburg D. Vitronectin inhibits the thrombotic response to arterial injury in mice. *Blood* 1999; **93**: 1825–30.
- Zheng X, Saunders TL, Camper SA, Samuelson LC, Ginsburg D. Vitronectin is not essential for normal mammalian development and fertility. *Proc Natl Acad Sci U S A* 1995; **92**: 12426–30.
- Eitzman DT, McCoy RD, Zheng X, Fay WP, Shen T, Ginsburg D, Simon RH. Bleomycin-induced pulmonary fibrosis in transgenic mice that either lack or overexpress the murine plasminogen activator inhibitor-1 gene. *J Clin Invest* 1996; **97**: 232–7.
- Wojcik BM, Wroblewski SK, Hawley AE, Wakefield TW, Myers DD Jr, Diaz JA. Interleukin-6: a potential target for post-thrombotic syndrome. *Ann Vasc Surg* 2011; **25**: 229–39.
- Myers D Jr, Farris D, Hawley A, Wroblewski S, Chapman A, Stoolman L, Knibbs R, Strieter R, Wakefield T. Selectins influence thrombosis in a mouse model of experimental deep venous thrombosis. *J Surg Res* 2002; **108**: 212–21.
- Henke PK, Varma MR, Moaveni DK, Dewyer NA, Moore AJ, Lynch EM, Longo C, Deatrck CB, Kunkel SL, Upchurch GR Jr, Wakefield TW. Fibrotic injury after experimental deep vein thrombosis is determined by the mechanism of thrombogenesis. *Thromb Haemost* 2007; **98**: 1045–55.
- Eagleton MJ, Peterson DA, Sullivan VV, Roelofs KJ, Ford JA, Stanley JC, Upchurch GR. Nitric oxide inhibition increases aortic wall matrix metalloproteinase-9 expression. *J Surg Res* 2002; **104**: 15–21.
- Dorffler-Melly J, Schwarte LA, Ince C, Levi M. Mouse models of focal arterial and venous thrombosis. *Basic Res Cardiol* 2000; **95**: 503–9.
- Upchurch GR, Ford JW, Weiss SJ, Knipp BS, Peterson DA, Thompson RW, Eagleton MJ, Broady AJ, Proctor MC, Stanley JC. Nitric oxide inhibition increases matrix metalloproteinase-9 expression by a rat aortic smooth muscle cells *in vitro*. *J Vasc Surg* 2001; **34**: 76–83.
- Ginzinger DG. Gene quantification using real-time quantitative PCR: an emerging technology hits the mainstream. *Exp Hematol* 2002; **30**: 503–12.
- Henke PK, Varga A, De S, Deatrck CB, Eliason J, Arenberg DA, Sukheepod P, Thanaporn P, Kunkel SL, Upchurch GR Jr, Wakefield TW. Deep vein thrombosis resolution is modulated by monocyte CXCR2-mediated activity in a mouse model. *Arterioscler Thromb Vasc Biol* 2004; **24**: 1130–7.
- Henke PK, Pearce CG, Moaveni DM, Moore AJ, Lynch EM, Longo C, Varma M, Dewyer NA, Deatrck KB, Upchurch GR Jr, Wakefield TW, Hogaboam C, Kunkel SL. Targeted deletion

- of CCR2 impairs deep vein thrombosis resolution in a mouse model. *J Immunol* 2006; **177**: 3388–97.
- 31 Diaz JA, Ballard-Lipka NE, Farris DM, Hawley AE, Wroblewski SK, Myers DD, Henke PK, Lawrence DA, Wakefield TW. Impaired fibrinolytic system in ApoE gene-deleted mice with hyperlipidemia augments deep vein thrombosis. *J Vasc Surg* 2012; **55**: 815–22.
 - 32 Junqueira LC, Bignolas G, Brentani RR. Picrosirius staining plus polarization microscopy, a specific method for collagen detection in tissue sections. *Histochem J* 1979; **11**: 447–55.
 - 33 Cuttle L, Nataatmadja M, Fraser JF, Kempf M, Kimble RM, Hayes MT. Collagen in the scarless fetal skin wound: detection with picrosirius-polarization. *Wound Repair Regen* 2005; **13**: 198–204.
 - 34 Moaveni DK, Lynch EM, Luke C, Sood V, Upchurch GR, Wakefield TW, Henke PK. Vein wall re-endothelialization after deep vein thrombosis is improved with low-molecular-weight heparin. *J Vasc Surg* 2008; **47**: 616–24.
 - 35 Henke PK, Mitsuya M, Luke CE, Elfine MA, Baldwin JF, Deatrck KB, Diaz JA, Sood V, Upchurch GR, Wakefield TW, Hogaboam C, Kunkel SL. Toll-like receptor 9 signaling is critical for early experimental deep vein thrombosis resolution. *Arterioscler Thromb Vasc Biol* 2011; **31**: 43–9.
 - 36 Sood V, Luke CE, Deatrck KB, Baldwin J, Miller EM, Elfine M, Upchurch GR Jr, Wakefield TW, Henke PK. Urokinase plasminogen activator independent early experimental thrombus resolution: MMP2 as an alternative mechanism. *Thromb Haemost* 2011; **104**: 1174–83.
 - 37 Laser A, Elfine M, Luke C, Slack D, Shah A, Sood V, Deatrck B, McEvoy B, Ostra C, Comerota A, Kunkel S, Hogaboam C, Henke PK. Deletion of cysteine-cysteine receptor 7 promotes fibrotic injury in experimental post-thrombotic vein wall remodeling. *Arterioscler Thromb Vasc Biol* 2014; **34**: 377–85.
 - 38 Zeisberg EM, Tarnavski O, Zeisberg M, Dorfman AL, McMullen JR, Gustafsson E, Chandraker A, Yuan X, Pu WT, Roberts AB, Neilson EG, Sayegh MH, Izumo S, Kalluri R. Endothelial-to-mesenchymal transition contributes to cardiac fibrosis. *Nat Med* 2007; **13**: 952–61.
 - 39 Hogaboam CM, Steinhilber ML, Chensue SW, Kunkel SL. Novel roles for chemokines and fibroblasts in interstitial fibrosis. *Kidney Int* 1998; **54**: 2152–9.
 - 40 Humphries J, McGuinness CL, Smith A, Waltham M, Poston R, Burnand KG. Monocyte chemoattractant protein-1 (MCP-1) accelerates the organization and resolution of venous thrombi. *J Vasc Surg* 1999; **30**: 894–9.
 - 41 Wakefield TW, Myers DD, Henke PK. Mechanisms of venous thrombosis and resolution. *Arterioscler Thromb Vasc Biol* 2008; **28**: 387–91.
 - 42 Legrand C, Polette M, Tournier JM, de Bentzmann S, Huet E, Monteau M, Birembaut P. uPA/plasmin system-mediated MMP-9 activation is implicated in bronchial epithelial cell migration. *Exp Cell Res* 2001; **264**: 326–36.
 - 43 Gong Y, Hart E, Shchurin A, Hoover-Plow J. Inflammatory macrophage migration requires MMP-9 activation by plasminogen in mice. *J Clin Invest* 2008; **118**: 3012–24.
 - 44 Takano A, Hirata A, Inomata Y, Kawaji T, Nakagawa K, Nagata S, Tanihara H. Intravitreal plasmin injection activates endogenous matrix metalloproteinase-2 in rabbit and human vitreous. *Am J Ophthalmol* 2005; **140**: 654–60.
 - 45 Bevilacqua MP, Schleef RR, Gimbrone MA Jr, Loskutoff DJ. Regulation of the fibrinolytic system of cultured human vascular endothelium by interleukin 1. *J Clin Invest* 1986; **78**: 587–91.
 - 46 Schleef RR, Bevilacqua MP, Sawdey M, Gimbrone MA Jr, Loskutoff DJ. Cytokine activation of vascular endothelium. Effects on tissue-type plasminogen activator and type 1 plasminogen activator inhibitor. *J Biol Chem* 1988; **263**: 5797–803.
 - 47 Libby P, Simon DI. Inflammation and thrombosis: the clot thickens. *Circulation* 2001; **103**: 1718–20.
 - 48 van de Craen B, Declercq PJ, Gils A. The Biochemistry, Physiology and Pathological roles of PAI-1 and the requirements for PAI-1 inhibition in vivo. *Thromb Res* 2012; **130**: 576–85.
 - 49 Obi AT, Diaz JA, Ballard-Lipka NL, Roelofs KJ, Farris DM, Lawrence DA, Henke PK, Wakefield TW. Low-molecular-weight heparin modulates vein wall fibrotic response in a plasminogen activator inhibitor 1-dependent manner. *J Vasc Surg Venous Lymphat Disord* 2014; in press.
 - 50 Carmeliet P, Moons L, Lijnen R, Janssens S, Lupu F, Collen D, Gerard RD. Inhibitory role of plasminogen activator inhibitor-1 in arterial wound healing and neointima formation: a gene targeting and gene transfer study in mice. *Circulation* 1997; **96**: 3180–91.
 - 51 Zhu Y, Farrehi PM, Fay WP. Plasminogen activator inhibitor type 1 enhances neointima formation after oxidative vascular injury in atherosclerosis-prone mice. *Circulation* 2001; **103**: 3105–10.
 - 52 Deatrck KB, Luke CE, Elfine MA, Sood V, Baldwin J, Upchurch GR Jr, Jaffer FA, Wakefield TW, Henke PK. The effect of matrix metalloproteinase 2 and matrix metalloproteinase 2/9 deletion in experimental post-thrombotic vein wall remodeling. *J Vasc Surg* 2013; **58**: 1375–84 e2.
 - 53 Deatrck KB, Obi A, Luke CE, Elfine MA, Sood V, Upchurch GR Jr, Jaffer F, Wakefield TW, Henke PK. Matrix metalloproteinase-9 deletion is associated with decreased mid-term vein wall fibrosis in experimental stasis DVT. *Thromb Res* 2013; **132**: 360–6.
 - 54 Martinez FO, Sica A, Mantovani A, Locati M. Macrophage activation and polarization. *Front Biosci* 2008; **13**: 453–61.
 - 55 Wilson MS, Madala SK, Ramalingam TR, Gochuico BR, Rosas IO, Cheever AW, Wynn TA. Bleomycin and IL-1beta-mediated pulmonary fibrosis is IL-17A dependent. *J Exp Med* 2010; **207**: 535–52.
 - 56 Zhu Z, Homer RJ, Wang Z, Chen Q, Geba GP, Wang J, Zhang Y, Elias JA. Pulmonary expression of interleukin-13 causes inflammation, mucus hypersecretion, subepithelial fibrosis, physiologic abnormalities, and eotaxin production. *J Clin Invest* 1999; **103**: 779–88.
 - 57 Fogo AB. Renal fibrosis: not just PAI-1 in the sky. *J Clin Invest* 2003; **112**: 326–8.
 - 58 Li R, Ren M, Chen N, Luo M, Zhang Z, Wu J. Vitronectin increases vascular permeability by promoting VE-cadherin internalization at cell junctions. *PLoS ONE* 2012; **7**: e37195.
 - 59 Kahn SR, Shapiro S, Wells PS, Rodger MA, Kovacs MJ, Anderson DR, Tagalakakis V, Houweling AH, Ducruet T, Holcroft C, Johri M, Solymoss S, Miron MJ, Yeo E, Smith R, Schulman S, Kassis J, Kearon C, Chagnon I, Wong T, et al. Compression stockings to prevent post-thrombotic syndrome: a randomised placebo-controlled trial. *Lancet* 2013; **383**: 880–3.
 - 60 Kearon C, Akl EA, Comerota AJ, Prandoni P, Bounameaux H, Goldhaber SZ, Nelson ME, Wells PS, Gould MK, Dentali F, Crowther M, Kahn SR. Antithrombotic therapy for VTE disease: antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. *Chest* 2012; **141**: e419S–94S.
 - 61 Podor TJ, Peterson CB, Lawrence DA, Stefansson S, Shaughnessy SG, Foulon DM, Butcher M, Weitz JI. Type 1 plasminogen activator inhibitor binds to fibrin via vitronectin. *J Biol Chem* 2000; **275**: 19788–94.